Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2355439 | 0.81 | MAPT (0.42) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL7033371 | 0.81 | MAPT (0.42) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL16325251 | 0.81 | MAPT (0.38) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL1470884 | 0.81 | MAPT (0.38) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL40410 | 0.77 | MAPT (0.41) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL40408 | 0.76 | MAPT (0.40) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL840792 | 0.75 | MAPT (0.41) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL2547799 | 0.74 | MAPT (0.39) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL11316383 | 0.74 | MAPT (0.39) | MAPTESR1ESR2MGAMNR1H2 | |
| SCHEMBL11316112 | 0.71 | MAPT (0.41) | MAPTESR1ESR2MGAMNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025053792-A1 | COLLECTIVE SYNTHESIS OF PHANTOMOLIN FAMILY THROUGH TOTAL SYNTHESIS OF THE SESQUITERPENE LACTONE MOLEPHANTIN | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-03-13 | — | — | WO | claimed |
| EP-3494996-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AGENSYS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEAGEN INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-12257340-B2 | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof | AGENSYS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2025053792-A1 | COLLECTIVE SYNTHESIS OF PHANTOMOLIN FAMILY THROUGH TOTAL SYNTHESIS OF THE SESQUITERPENE LACTONE MOLEPHANTIN | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-03-13 | — | — | WO | disclosed |
| EP-3581206-B1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE P13K-AKT MTOR PATHWAY | SEAGEN INC (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240131176-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | SEAGEN INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240043556-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-6018056-A | Intermediates and processes for preparing benzo (b) thiophenes | ELI LILLY AND COMPANY (US) | 2000-01-25 | — | — | US | disclosed |
| US-5908859-A | ESPECIALLY HYPERCHOLESTEROLEMIA | ELI LILLY AND COMPANY (US) | 1999-06-01 | — | — | US | disclosed |
| EP-0902025-A2 | Benzothiophenes for treatment of estrogen related conditions | ELI LILLY AND COMPANY (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0897903-A2 | Ketone-derivatives of indene, dihydronaphthalene or naphthalene compounds for the treatment of hyperlipidemia | ELI LILLY AND COMPANY (US) | 1999-02-24 | — | — | EP | disclosed |
| EP-0897918-A1 | Benzothiophene derivatives and their use as pharmaceutically active agents | ELI LILLY AND COMPANY (US) | 1999-02-24 | — | — | EP | disclosed |
| US-5852193-A | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals | ELI LILLY AND COMPANY (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0878474-A2 | Intermediates and a process for preparing benzo[b]thiophenes | ELI LILLY AND COMPANY (US) | 1998-11-18 | — | — | EP | disclosed |
| WO-1998048792-A1 | A REGIOSELECTIVE ALKYLATION PROCESS FOR PREPARING SUBSTITUTED BENZO[b]THIOPHENES | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0875507-A1 | Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| EP-0875510-A1 | Process for preparing benzothiophenes | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | MTOR, RICTOR, PIK3R5 | MAPT 2322/4885ESR1 1225/4885ESR2 1868/4885 |
| US-20240131176-A1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY | MTOR, RICTOR, PIK3R5 | MAPT 2322/4885ESR1 1225/4885ESR2 1868/4885 |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | CD44, CA12, H1-10 | MAPT 424/4885ESR1 4078/4885ESR2 4183/4885 |
| US-20240043556-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | LGALS3BP, PABPC4, PA2G4 | MAPT 752/4885ESR1 3066/4885ESR2 3498/4885 |
| US-12257340-B2 | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof | TMED10, CD44, CA12 | MAPT 115/4885ESR1 4713/4885ESR2 4711/4885 |
| US-20230346968-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, CD2BP2, PA2G4 | MAPT 882/4885ESR1 2069/4885ESR2 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.